IceCure CFO Departs as Firm Enters Critical Commercialization Phase

CAESAREA, Israel – February 09, 2026 – IceCure Medical Ltd. (Nasdaq: ICCM) announced today the planned departure of Chief Financial Officer Ronen Tsimerman, a move that comes at a pivotal moment for the medical device company. After nearly a decade of steering the company's finances through crucial development milestones, Tsimerman's exit coincides with IceCure's transition into the high-stakes commercialization of its newly FDA-cleared breast cancer treatment, ProSense®.

The company has initiated a search for a successor, stating it has identified compelling candidates with experience in commercializing disruptive technologies. Tsimerman will remain in his role until a new CFO is appointed to ensure a seamless transition.

An Era of Key Milestones

Ronen Tsimerman's nine-year tenure was instrumental in transforming IceCure from a development-stage company into a publicly traded entity with a market-authorized product in the United States. His financial leadership was central to achieving several key objectives that laid the groundwork for the company's current position.

Under his watch, IceCure successfully listed on the Nasdaq exchange, significantly raising its profile with international investors. He also oversaw critical fundraising campaigns that provided the capital necessary to complete the landmark ICE3 clinical trial. The ICE3 study was the largest of its kind for cryoablation in breast cancer and formed the bedrock of the company's submission to U.S. regulators.

This journey culminated in late 2025 with the U.S. Food and Drug Administration (FDA) granting marketing clearance for the ProSense® Cryoablation System. The clearance, a monumental achievement for the company, was specifically for the treatment of low-risk breast cancer in certain patient populations.

"Ronen has been a valued contributor over the years, and his skilled financial and operational leadership allowed IceCure Medical to achieve several key milestones," stated IceCure's CEO, Eyal Shamir, in a press release. "We wish him well in his future endeavors and are pleased to have his continued support over the next few months as we transition to a new CFO."

Tsimerman expressed his pride in the company's accomplishments. "Our mission and the collaborative work... to bring the first and only on-label treatment in the U.S. for the minimally invasive treatment of low-risk breast cancer is truly an amazing accomplishment," he stated.

The Commercialization Challenge

The departure comes just as IceCure embarks on its most critical and capital-intensive phase yet: the full-scale commercial launch of ProSense® in the lucrative U.S. market. The system, which uses liquid nitrogen to freeze and destroy tumors, is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, particularly those who are not suitable surgical candidates.

This specific indication opens a significant market opportunity. An estimated 46,000 women in the U.S. are diagnosed annually with this type of low-risk breast cancer. The broader cancer cryotherapy market is also on a strong growth trajectory, projected to expand from approximately $428 million in 2025 to over $780 million by 2035, driven by a growing demand for minimally invasive procedures.

To capitalize on this, IceCure has been preparing for an aggressive market rollout. The company's sales and marketing expenses surged by 42% in 2024 to $6.3 million as it built out its commercial infrastructure in anticipation of the FDA's decision. This investment is now being put to the test as the sales team engages with hospitals, clinics, and physicians across the country. The company has already reported strong initial demand in the U.S. and record sales in Europe following the news.

A Financial Tightrope Walk

While the FDA clearance provides a powerful tailwind, the company's financial statements reveal the challenging realities of a pre-profit medical device firm. IceCure is navigating a period of high cash burn as it invests heavily in its commercial launch. Preliminary estimates show the company held approximately $8.9 million in cash and cash equivalents as of December 31, 2025.

This cash position is set against a backdrop of continued net losses. For the first nine months of 2025, IceCure reported a net loss of $10.8 million on revenues of $2.1 million. While preliminary full-year 2025 revenues hit a record of approximately $3.4 million, profitability remains a distant goal. This financial picture underscores the critical importance of the incoming CFO, who will be tasked with managing the company's runway and securing its financial future during this pivotal growth stage.

Investor sentiment reflects this duality of promise and risk. The company's stock (ICCM) has declined over the past year, and the consensus analyst rating is a "Hold." However, the consensus price target of around $2.64 suggests a significant potential upside from its current trading price of approximately $0.60. A recent decrease in short interest by over 36% also indicates that some investors are growing more optimistic about the company's prospects.

As IceCure searches for a new financial chief, the focus is clearly on execution. The new leadership will inherit the legacy of Tsimerman's foundational work but will face the immediate pressure of turning regulatory success into commercial revenue and steering the company toward a sustainable financial path.